Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM159PT | TNBC | Basal B | GSK923295 | CENPE | Kinesin | 0.000427 | uM | 7920.001 | 1.0419 | 1.0187 | 4.4085 | |
| SUM159PT | TNBC | Basal B | GSK923295 | CENPE | Kinesin | 0.267 | uM | 7920.001 | 0.1187 | 0.2333 | 4.4085 | |
| SUM159PT | TNBC | Basal B | GSK923295 | CENPE | Kinesin | 33.3 | uM | 7920.001 | 0.0530 | 0.0271 | 4.4085 | |
| SUM159PT | TNBC | Basal B | GSK923295 | CENPE | Kinesin | 6.67 | uM | 7920.001 | 0.1598 | 0.3193 | 4.4085 | |
| SUM159PT | TNBC | Basal B | GSK461364 | PLK1 | PLK | 1.33 | uM | 7920.001 | 0.0527 | 0.0258 | 4.4085 | |
| SUM159PT | TNBC | Basal B | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.201 | uM | 7920.075 | 0.9319 | 0.9694 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Gemcitabine | DNA replication | DNA replication | 722 | uM | 7920.075 | 0.0589 | 0.0776 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Oxaliplatin | DNA cross-linker | DNA cross-linker | 629 | uM | 7920.075 | 0.0149 | -0.2022 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Carboplatin | DNA cross-linker | DNA cross-linker | 1350 | uM | 7920.075 | 0.0088 | -0.2887 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Oxaliplatin | DNA cross-linker | DNA cross-linker | 126 | uM | 7920.075 | 0.0167 | -0.1818 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Gemcitabine | DNA replication | DNA replication | 0.00924 | uM | 7920.075 | 0.8816 | 0.9457 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Oxaliplatin | DNA cross-linker | DNA cross-linker | 1.01 | uM | 7920.075 | 0.7522 | 0.8794 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Carboplatin | DNA cross-linker | DNA cross-linker | 269 | uM | 7920.075 | 0.0131 | -0.2246 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Oxaliplatin | DNA cross-linker | DNA cross-linker | 25.2 | uM | 7920.075 | 0.1800 | 0.3752 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Gemcitabine | DNA replication | DNA replication | 144 | uM | 7920.075 | 0.0485 | 0.0327 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Oxaliplatin | DNA cross-linker | DNA cross-linker | 5.04 | uM | 7920.075 | 0.3125 | 0.5513 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Carboplatin | DNA cross-linker | DNA cross-linker | 10.8 | uM | 7920.075 | 0.9208 | 0.9643 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.0403 | uM | 7920.075 | 0.9769 | 0.9898 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Gemcitabine | DNA replication | DNA replication | 0.00185 | uM | 7920.075 | 0.9397 | 0.9730 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.00806 | uM | 7920.075 | 0.9736 | 0.9883 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Carboplatin | DNA cross-linker | DNA cross-linker | 53.9 | uM | 7920.075 | 0.4540 | 0.6832 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.00161 | uM | 7920.075 | 0.9838 | 0.9929 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Gemcitabine | DNA replication | DNA replication | 0.231 | uM | 7920.075 | 0.0749 | 0.1357 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Carboplatin | DNA cross-linker | DNA cross-linker | 2.16 | uM | 7920.075 | 0.9675 | 0.9856 | 4.5785 | |
| SUM159PT | TNBC | Basal B | Gemcitabine | DNA replication | DNA replication | 0.0462 | uM | 7920.075 | 0.1580 | 0.3366 | 4.5785 |